Does Rallies show Form 4 insider transactions for EYPT?

Yes. Rallies tracks EYPT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is EYPT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EYPT. It does not provide personalized investment advice.

EYPT (EyePoint, Inc. Common Stock) Stock Analysis - Insider Trades

EyePoint, Inc. Common Stock (EYPT) is a publicly traded Healthcare sector company. As of May 21, 2026, EYPT trades at $12.53 with a market cap of $980.94M and a P/E ratio of -3.95. EYPT moved +5.92% today. Year to date, EYPT is -28.28%; over the trailing twelve months it is +101.29%. Its 52-week range spans $3.91 to $19.11. Analyst consensus is strong buy with an average price target of $36.40. Rallies surfaces EYPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading EYPT stock inside the company?

Recent EYPT insider activity includes Ribeiro Ramiro sold 2.44K, Duker Jay S. bought 1.50K, Ribeiro Ramiro sold 2.44K, Ribeiro Ramiro sold 2.44K, and Ribeiro Ramiro sold 42.54K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

EYPT Key Metrics

Key financial metrics for EYPT
Metric	Value
Price	$12.53
Market Cap	$980.94M
P/E Ratio	-3.95
EPS	$-3.17
Dividend Yield	0.00%
52-Week High	$19.11
52-Week Low	$3.91
Volume	7.81K
Avg Volume	0
Revenue (TTM)	$31.37M
Net Income	$-231.96M
Gross Margin	0.00%

Recent EYPT Insider Trades

Ribeiro Ramiro sold 2.44K (~$36.55K) on Apr 17, 2026.
Duker Jay S. bought 1.50K (~$19.72K) on Mar 16, 2026.
Ribeiro Ramiro sold 2.44K (~$43.57K) on Mar 4, 2026.
Ribeiro Ramiro sold 2.44K (~$36.55K) on Feb 17, 2026.
Ribeiro Ramiro sold 42.54K (~$727.32K) on Jan 5, 2026.

Latest EYPT News

EyePoint’s DURAVYU Phase 3 Trials Secure Third DSMC Review with 35% Third Dose — May 14, 2026
EyePoint Posts $84.8M Q1 Loss, Holds $223M Cash for Mid-2026 Readouts — May 6, 2026
EyePoint Raises $306M Runway, Phase 3 DME Dosing and Mid-2026 Wet AMD Data — Mar 4, 2026
EyePoint Secures $300M Cash Runway into Q4 2027, Phase 3 DURAVYU Trials On Track — Mar 4, 2026
EyePoint Appoints Veteran Commercial Leader with 175,000 Options for DURAVYU Phase 3 Launch — Feb 18, 2026

EYPT Analyst Consensus

10 analysts cover EYPT: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.40.

Common questions about EYPT

Who is trading EYPT stock inside the company?: Recent EYPT insider activity includes Ribeiro Ramiro sold 2.44K, Duker Jay S. bought 1.50K, Ribeiro Ramiro sold 2.44K, Ribeiro Ramiro sold 2.44K, and Ribeiro Ramiro sold 42.54K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for EYPT?: Yes. Rallies tracks EYPT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is EYPT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EYPT. It does not provide personalized investment advice.